Harbor Capital Advisors, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Harbor Capital Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 08, 2024	BUY	$31.73 - $49.19 $96,713 - $149,931	3,048 Added 9.56%	34,930 $1.67 Million
Q3 2023 Oct 20, 2023	BUY	$34.92 - $46.66 $206,377 - $275,760	5,910 Added 22.76%	31,882 $1.14 Million
Q2 2023 Jul 11, 2023	BUY	$37.35 - $52.15 $970,054 - $1.35 Million	25,972 New	25,972 $1.2 Million
Q4 2022 Jan 20, 2023	BUY	$33.72 - $46.33 $15,814 - $21,728	469 Added 26.13%	2,264 $0
Q3 2022 Oct 28, 2022	SELL	$39.96 - $66.14 $44,875 - $74,275	-1,123 Reduced 38.49%	1,795 $74,000
Q2 2022 Jul 26, 2022	BUY	$45.8 - $85.4 $27,113 - $50,556	592 Added 25.45%	2,918 $174,000
Q1 2022 Apr 28, 2022	BUY	$62.2 - $84.4 $144,677 - $196,314	2,326 New	2,326 $169,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.